INNOVENT BIO (01801) saw a sharp decline of over 6%, dropping 5.43% to HK$87 by the time of writing, with a trading volume of HK$1.86 billion. The company successfully included seven innovative products (including new indications) in the latest national medical insurance catalog. Among them is the expanded indication for its PD-1 inhibitor, Tyvyt (sintilimab injection), with all eight approved indications now covered by insurance. The list also features several newly launched drugs targeting oncology and chronic diseases. Notably, INNOVENT BIO recently completed a strategic investment from Takeda Pharmaceutical, issuing 6.9138 million shares (approximately 0.4% of issued share capital) for a net proceeds of around HK$780 million. Additionally, pre-market block trades involved approximately 13.0734 million shares at an average price of HK$92 per share, totaling over HK$1.2 billion.